Aztreonam-avibactam Demonstrates Potent Activity Against Carbapenem-resistant Enterobacterales Collected From US Medical Centers Over a 6-year Period (2017–2022)
Aztreonam-avibactam demonstrates potent activity toward CREs with different carbapenem-resistance mechanisms. The combination is an anticipated welcome addition to the clinician's toolbox giving physicians another option to treat CREs.
Authors
- Joshua Maher (ORCID: https://orcid.org/0000-0002-2841-6855)
- Krisztina M. Papp‐Wallace (ORCID: https://orcid.org/0000-0002-9976-7898)
- John H. Kimbrough (ORCID: https://orcid.org/0000-0002-0457-1543)
- Mariana Castanheira (ORCID: https://orcid.org/0000-0003-0126-1782)
- Hélio S. Sader (ORCID: https://orcid.org/0000-0001-7022-6644)
Institutions
- JMI Laboratories (US)
Publication Details
- Journal
- Open Forum Infectious Diseases
- Published
- 2025-04-25
- DOI
- https://doi.org/10.1093/ofid/ofaf250
- Citations
- 8
- Primary Topic
- Antibiotic Resistance in Bacteria
- Type
- article
- Field-Weighted Citation Impact
- 4.73